Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Vanda Pharmaceuticals

Status and phase: Enrolling; Phase 3

Conditions: Motion Sickness

Treatments: Drug: Tradipitant

Study type: Interventional

Funder types: Industry

Identifiers

NCT06138613

VP-VLY-686-3403

Details and patient eligibility

About

An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel

Full description

This is an open label study to investigate the efficacy and safety of tradipitant in motion sickness affected male and female participants during events historically known to cause motion sickness.

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of Motion Sickness
• Age 18-75

Exclusion criteria

• Nausea-inducing disorder other than motion sickness
• BMI > 40
• History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

500 participants in 2 patient groups

Tradipitant Dose A

Experimental group

Description:

"See Drug"

Treatment:

Drug: Tradipitant

Tradipitant Dose B

Experimental group

Description:

"See Drug"

Treatment:

Drug: Tradipitant